“…DEHP, being a metabolic disruptor, can disrupt the metabolic homeostasis of lipid molecules typically by activation of the nuclear peroxisome proliferator-activated receptors, leading to a series of adverse effects on health (e.g., nonalcoholic fatty liver disease). − Fish exposure studies have showed that DEHP interferes with the metabolism of lipids, with the most-affected metabolites including PLs (PCs and PEs), LPLs (LPEs and lysophosphatidates), GLs (DGs and triacylglycerols), sphingolipids (Sphs; sphingosines and sphingomyelins), and FAs. , Similarly, in liver tissues of mice or rats exposed to DEHP, the most-affected pathways have been found to be those involved in the metabolism of lipids such as PLs, LPLs, GLs, Sphs, cholesterol esters (CEs), and FAs. , Thus, PLs, LPLs, GLs, Sphs, CEs, and FAs are the lipid metabolites that are primarily affected by exposure to DEHP via a peroxisome proliferator-activated receptor-mediated pathway. In the current study, H–D exchange experiments revealed that DEHP competes with D-labeled lipids for binding to the pocket of enzymes involved in lipid biotransformation, and in vitro and in vivo exposure experiments showed that this process may affect the concentrations of endogenous PLs, LPLs, CLs, and MLCLs (as shown in Figure a) through interference with the catabolism or anabolism of these endogenous metabolites.…”